doranidazole has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, M; Ogino, H; Shibamoto, Y; Sugie, C | 1 |
| Shibamoto, Y | 1 |
| Ariga, H; Baba, Y; Ebe, K; Nemoto, K; Ohmagari, J; Ouchi, A; Sakaguchi, M; Sakamoto, K; Sasai, K; Shibamoto, Y; Shinozaki, M; Takai, Y; Tsujitani, M; Yamada, S | 1 |
2 review(s) available for doranidazole and Neoplasms
| Article | Year |
|---|---|
The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.
Topics: Asian People; Cell Hypoxia; Clinical Trials as Topic; Humans; Imidazoles; Neoplasms; Nitroimidazoles; Prodrugs; Radiation; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 2004 |
[Contribution of radiation biology to the development of radiation therapy].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose Fractionation, Radiation; Humans; Imidazoles; Lung Neoplasms; Neoplasms; Nimorazole; Radiation-Sensitizing Agents; Triazoles | 1999 |
1 trial(s) available for doranidazole and Neoplasms
| Article | Year |
|---|---|
Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy.
Topics: Adult; Aged; Area Under Curve; Cell Hypoxia; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2001 |